0001104659-23-081715.txt : 20230717
0001104659-23-081715.hdr.sgml : 20230717
20230717182213
ACCESSION NUMBER: 0001104659-23-081715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230714
FILED AS OF DATE: 20230717
DATE AS OF CHANGE: 20230717
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vogt Frederick G
CENTRAL INDEX KEY: 0001719678
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 231092585
MAIL ADDRESS:
STREET 1: 2120 HEMLOCK RD.
CITY: WEST NORRITON
STATE: PA
ZIP: 19403
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD
STREET 2: 4TH FLOOR
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm2321428-3_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-14
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001719678
Vogt Frederick G
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
CA
94070
0
1
0
0
Interim CEO & General Counsel
0
Common Stock
2023-07-14
4
M
0
20834
0
A
81701
D
Common Stock
2023-07-14
4
F
0
8851
7.76
D
72850
D
Restricted Stock Units
2023-07-14
4
M
0
20834
0.00
D
Common stock
20834
125007
D
Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
Represents common stock remaining after deducting the common stock withheld for taxes.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The remaining RSUs will vest in six equal quarterly installments.
/s/ Frederick G. Vogt
2023-07-17